324 results
P
B-cell lymphoma patients
I/C
CAR-T cell technology
O
response rate, complete remission rate, toxicity (cytokine-releasing syndrome [CRS], neurotoxicity)
P
large B cell lymphoma (LBCL) patients with central nervous system (CNS) involvement
I/C
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy
O
overall response (ORR), complete response (CR), overall survival (OS), progression free survival (PFS), severe immune effector cell-associated neurotoxicity syndrome, severe cytokine release syndrome
P
ALL, NHL
I/C
CD22 CAR T-cells, CD19/CD22 CAR T-cells, anti-CD19 CAR T-cells
O
best complete response (bCR)
P
patients with large B cell lymphoma (LBCL)
I/C
bridging therapy (BT), CAR-T therapy
O
poorer overall survival, 1-year progression-free survival, complete response rate, and grade ≥3 immune effector cell-associated neurotoxicity syndrome
P
individuals with depressive disorders, individuals with anxiety disorders, nonclinical comparison groups
I/C
STAI-T scores, scores on the STAI-T compared to nonclinical comparison groups, anxiety and depressive symptom severity were similarly strongly correlated with the STAI-T
O
elevated scores on the STAI-T, strongly correlated with the STAI-T, significantly higher STAI-T scores than individuals with an anxiety disorder
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
Hepatitis B virus (HBV) chronic infection patients
I/C
Nucleos(t)ide analogues (NA), plasma exchange, rituximab
O
suppression of HBV replication, clinical response, severe or life-threatening cases
P
adult patients with clinically negative neck (cN0) PTC
I/C
T+CND, T
O
structural and biochemical recurrence, complications, permanent hypoparathyroidism
P
pediatric and young adult population
I/C
CD19-specific CAR-T therapy
O
complete remission, relapse, adverse events, minimal residual negative complete remission
P
1200 participants
I/C
Acupuncture alone, Acupuncture combined with vitamin B, Vitamin B
O
Clinical efficacy